Corticosterone inhibits GAS6, affecting hairfolliclestem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfolliclestem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfolliclestem cells, but minoxidil and finasteride are still the main treatments.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hairfollicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.